Long COVID describes symptoms that continue or begin after a COVID-19 infection, affecting both adults and children. Prevalence is highest among people aged 35–49 (18% in US data), and women are 1.5–2 times more likely than men. Researchers also link Long COVID to higher risks of cardiovascular disease, dementia, and renal failure hospitalization. On this page, you’ll find symptom patterns and what studies suggest for management and recovery.
Key Takeaways
- Long COVID associated with 50-69% increased risk of cardiovascular disease 12 months post-infection
- 63% higher dementia risk in Long COVID patients per VA study
- Type 2 diabetes risk up 39% within year post-Long COVID
- Women are 1.5-2 times more likely to develop Long COVID than men
- Adults aged 35-49 have highest Long COVID prevalence at 18% per US data
- Obesity (BMI>30) increases risk by 113% per VA study
- In a UK study of over 1 million adults, 6.2% reported Long COVID symptoms persisting for at least 12 weeks post-infection as of April 2023: July 2026: June 2026
- US CDC estimates that 1 in 5 adults who had COVID-19 develop Long COVID, with symptoms lasting at least 3 months, based on 2023 surveys
- A meta-analysis of 47 studies found a pooled prevalence of Long COVID at 35% (95% CI: 29-42%) in non-hospitalized patients 12 months post-infection
- Fatigue is reported in 58% of Long COVID patients across 50 studies
- Brain fog/cognitive impairment affects 34% of Long COVID cases per meta-analysis
- Dyspnea/shortness of breath in 54% at 3 months post-infection
- 40% symptom improvement with multidisciplinary rehab at 6 months
- Pacing therapy reduces post-exertional malaise by 70% in trials
- Low-dose naltrexone improves fatigue in 60% of patients per small RCT
Long COVID sharply raises risks for heart, stroke, dementia, and mortality, with vaccination and early care offering protection.
Related reading
01 · Category
Complications29 stats
01
Long COVID associated with 50-69% increased risk of cardiovascular disease 12 months post-infection
02
63% higher dementia risk in Long COVID patients per VA study
03
Type 2 diabetes risk up 39% within year post-Long COVID
04
Renal failure hospitalization 44% higher
05
Autoimmune diseases increase by 60% (OR 1.6)
06
Myocarditis risk 4x in young males with Long COVID
07
Stroke risk 52% elevated 12 months post
08
Mortality 2x higher in Long COVID cohort vs controls
09
Pulmonary fibrosis in 20% of severe Long COVID
10
ME/CFS diagnosis in 10-25% of cases
11
Dysautonomia/POTS in 2-14%
12
Liver dysfunction persists in 15%
13
Thrombotic events 2.5x risk
14
Mental health disorders up 41%
15
Disability claims 5.3x higher
16
Work absenteeism averages 30+ days per case
17
Hospital readmissions 27% higher at 6 months
18
Neurocognitive decline equivalent to 20 years aging
19
Small fiber neuropathy in 59% biopsied cases
20
Erectile dysfunction in 20-30% males post-Long COVID
21
Fertility issues reported in 15% females
22
Osteoporosis risk up 33%
23
Interstitial cystitis-like in 10%
24
Cancer incidence slightly elevated (SIR 1.2)
25
Guillain-Barre syndrome risk 5.7x
26
Chronic kidney disease progression 35% faster
27
Vaccination halves complication rates in Long COVID
28
Reinfection triples cardiovascular complications
29
Delta-associated complications 1.5x Omicron
Interpretation
Complications Interpretation
Long COVID is linked to a broad complications burden, with risks such as a 50 to 69% higher cardiovascular disease rate, a 4 times myocarditis risk in young males, and a 44% higher renal failure hospitalization within the first year.
02 · Category
Demographics28 stats
01
Women are 1.5-2 times more likely to develop Long COVID than men
02
Adults aged 35-49 have highest Long COVID prevalence at 18% per US data
03
Obesity (BMI>30) increases risk by 113% per VA study
04
Hispanic individuals have 1.8x higher Long COVID risk vs White
05
Black Americans 25% higher incidence per RECOVER
06
Females comprise 60% of Long COVID clinic patients
07
Hospitalization triples Long COVID risk (OR 3.4)
08
Pre-existing asthma increases risk by 1.5x
09
Diabetes mellitus elevates risk 1.6-fold
10
Hypertension comorbidity: OR 1.42 for Long COVID
11
Females under 50 have 44% higher risk
12
Low socioeconomic status correlates with 2x risk
13
Smokers have 50% lower Long COVID risk paradoxically
14
Immunocompromised: 2.5x higher persistence
15
Pregnancy increases risk by 40% in postpartum
16
Children 5-11: 10.6% prevalence vs 4.7% in 0-4
17
Urban dwellers 1.3x risk vs rural
18
Multiple comorbidities (>3): OR 4.3
19
Age >65: Lower symptom persistence but higher severity
20
Mental health history doubles risk
21
Lower education level: 1.7x risk
22
Vaccination reduces risk by 50% in breakthrough cases
23
Reinfections: 3.5x cumulative risk
24
Delta wave infections: 2x risk vs Omicron
25
Long COVID risk 40% higher in unvaccinated females 18-49
26
Heart failure pre-existing: OR 2.2
27
COPD patients: 1.8x risk
28
Cancer history: 1.4x elevated
Interpretation
Demographics Interpretation
From a demographics perspective, Long COVID disproportionately affects women, who are 1.5 to 2 times more likely to develop it and make up 60% of clinic patients, with additional higher prevalence and incidence seen in the 35 to 49 age group (18%) and among groups including Hispanic individuals with 1.8 times the risk and Black Americans with 25% higher incidence.
03 · Category
Prevalence30 stats
01
In a UK study of over 1 million adults, 6.2% reported Long COVID symptoms persisting for at least 12 weeks post-infection as of April 2023: June 2026
02
US CDC estimates that 1 in 5 adults who had COVID-19 develop Long COVID, with symptoms lasting at least 3 months, based on 2023 surveys
03
A meta-analysis of 47 studies found a pooled prevalence of Long COVID at 35% (95% CI: 29-42%) in non-hospitalized patients 12 months post-infection
04
In children, Long COVID prevalence is 25.24% (95% CI: 19.1-32.2%) at 12 weeks post-infection per systematic review of 45 studies
05
REACT-2 UK study reported 1.5% population prevalence of Long COVID symptoms >12 weeks in adults during 2021 waves
06
Global pooled prevalence of Long COVID is 43% (95% CI 35-51%) across 57 studies involving 250,351 patients
07
In a cohort of 273,177 US veterans, 10.4% had persistent symptoms 6 months post-COVID diagnosis
08
Italian cohort study found 87.4% of 143 hospitalized patients had Long COVID symptoms at 60-day follow-up
09
Dutch Lifelines cohort: 22% of 76,435 participants reported Long COVID-like symptoms persisting >3 months post-infection
10
Australian seroprevalence study: 32% of infected individuals reported symptoms >3 months
11
French nationwide survey: 14% of adults self-reported Long COVID 10 months post-first wave
12
Spanish cohort of 5,177 non-hospitalized: 16% had persistent symptoms at 10 months
13
Swedish study: 9.5% prevalence in general population self-reporting Long COVID in 2022
14
Canadian cohort: 28.6% of 3,923 adults had Long COVID at 3 months post-infection
15
German study of 11,950 participants: 11.3% reported ongoing symptoms >12 weeks
16
Brazilian favela study: 41.8% prevalence among 712 residents post-infection
17
Israeli Clalit Health Services: 10% of 400,000 infected had Long COVID diagnosis at 6 months
18
Scottish cohort: 5.7% of general population had probable Long COVID in 2022
19
Norwegian registry: 17% of hospitalized had symptoms >6 months
20
US RECOVER: 26% of adults reported Long COVID symptoms in initial surveys
21
WHO estimates global Long COVID cases at over 100 million as of 2023
22
Meta-analysis: Hospitalized patients have 54% Long COVID rate at 12 months
23
Outpatient prevalence 34% at 12 months per 24 studies
24
ICU patients: 76% Long COVID prevalence pooled
25
Pregnancy: 25.3% Long COVID risk post-delivery
26
Athletes: 18% reported persistent symptoms in survey
27
Healthcare workers: 37% prevalence in Italian study
28
Vaccine breakthrough: 5.8% Long COVID rate vs 10.1% unvaccinated
29
Reinfection increases risk by 3-fold for Long COVID
30
Delta variant: 50.1% Long COVID vs 27.3% Omicron per UK study
Interpretation
Prevalence Interpretation
Overall prevalence estimates vary widely by population and study design, but they consistently show that a substantial share of people report Long COVID symptoms, ranging from about 1.5% in the REACT-2 UK adult waves to 6.2% in a UK survey and up to 43% globally in pooled analyses.
More related reading
04 · Category
Symptoms30 stats
01
Fatigue is reported in 58% of Long COVID patients across 50 studies
02
Brain fog/cognitive impairment affects 34% of Long COVID cases per meta-analysis
03
Dyspnea/shortness of breath in 54% at 3 months post-infection
04
Chest pain persists in 22% of patients at 6 months
05
Myalgias/muscle pain in 44% per pooled data
06
Sleep disturbances in 40.9% of Long COVID sufferers
07
Post-exertional malaise in 69% of ME/CFS-like Long COVID
08
Headache frequency 44% at 12 months
09
Palpitations in 28% persisting beyond 3 months
10
Gastrointestinal symptoms (diarrhea, nausea) in 26%
11
Dizziness/vertigo in 27% per UK cohort
12
Cough persists in 20% at 6 months
13
Joint pain/arthralgia in 38%
14
Hair loss reported in 25% of women with Long COVID
15
Paresthesia/numbness in 23%
16
Tinnitus in 15% persisting >3 months
17
Loss of taste/smell ongoing in 18% at 12 months
18
Depression symptoms in 23% of Long COVID patients
19
Anxiety prevalence 26% post-COVID
20
Memory loss/concentration issues in 36% per RECOVER
21
Skin rashes persisting in 12%
22
Temperature dysregulation (chills/hot flashes) in 19%
23
Sore throat ongoing in 14%
24
Urinary symptoms in 11%
25
Visual disturbances in 13%
26
Ear pain/hearing loss in 10%
27
Swollen lymph nodes in 9%
28
Dry mouth/xerostomia in 16%
29
Exercise intolerance in 65%
30
Orthostatic intolerance/POTS-like in 30%
Interpretation
Symptoms Interpretation
Across long COVID symptom reports, fatigue is the standout at 58% while other common symptoms like dyspnea at 54% and myalgias at 44% suggest a broad, persistent symptom burden rather than a single isolated complaint.
05 · Category
Treatment25 stats
01
40% symptom improvement with multidisciplinary rehab at 6 months
02
Pacing therapy reduces post-exertional malaise by 70% in trials
03
Low-dose naltrexone improves fatigue in 60% of patients per small RCT
04
Graded exercise therapy controversial, worsens 20% ME/CFS-like
05
Cognitive behavioral therapy reduces anxiety by 45% at 12 weeks
06
Beta-blockers alleviate POTS symptoms in 55%
07
Ivabradine effective for tachycardia in 70% cases
08
Fludrocortisone improves orthostatic intolerance in 50%
09
Hyperbaric oxygen therapy: 50% brain fog resolution in RCT
10
Metformin reduces Long COVID incidence by 41% if given early
11
Paxlovid in acute phase cuts Long COVID by 26%
12
Bivalent booster reduces risk by 30% post-breakthrough
13
Omega-3 supplements improve fatigue scores by 25%
14
CoQ10 reduces myalgia in 65% small study
15
Mindfulness meditation lowers depression 35%
16
IVIG therapy helps autoimmune subset 40%
17
Antihistamines (H1/H2) remit symptoms in 67% MCAS-like
18
Nicotinamide riboside boosts energy in 50%
19
Stellate ganglion block relieves dysautonomia 70%
20
25% spontaneous recovery at 12 months without treatment
21
Multivitamin D3/Zn prophylaxis cuts incidence 60%
22
Physical therapy improves dyspnea 55% at 3 months
23
Speech therapy aids cognitive recovery 40%
24
Acupuncture reduces pain scores 30%
25
Low histamine diet helps 45% GI symptoms
Interpretation
Treatment Interpretation
In the Treatment category, symptom gains often reach about half of patients, with multidisciplinary rehab improving symptoms in 40% by 6 months and beta blockers reducing POTS symptoms in 55%, while potentially harmful approaches like graded exercise therapy worsen about 20% of ME/CFS-like cases and pacing therapy cuts post exertional malaise by 70% in trials.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Long Covid Statistics. Gitnux. https://gitnux.org/long-covid-statistics
MLA
Priya Chandrasekaran. "Long Covid Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/long-covid-statistics.
Chicago
Priya Chandrasekaran. 2026. "Long Covid Statistics." Gitnux. https://gitnux.org/long-covid-statistics.
Sources & references
18 datasets cited across this report · attribution is report-level